Thalji Nassir M, Suri Rakesh M, Enriquez-Sarano Maurice, Gersh Bernard J, Huebner Marianne, Dearani Joseph A, Burkhart Harold M, Li Zhuo, Greason Kevin L, Michelena Hector I, Schaff Hartzell V
Mayo Clinic, Rochester, MN, USA.
Mayo Clinic, Rochester, MN, USA
Eur J Cardiothorac Surg. 2015 Apr;47(4):712-9. doi: 10.1093/ejcts/ezu231. Epub 2014 Jun 6.
Aortic valve replacement (AVR) for severe aortic valve stenosis (AS) is a Class I indication at the time of coronary artery bypass grafting (CABG). Management of less-than-severe AS in patients undergoing CABG is uncertain however, because the thresholds at which untreated AS impacts long-term outcome are unclear.
We identified 312 patients who underwent isolated CABG between 1993 and 2006 with mild or moderate AS [aortic valve area (AVA) 1-2 cm(2)], and matched them to patients undergoing CABG alone during the same period with similar characteristics but without AS (AVA >2 cm(2)). Long-term survival after CABG and its determinants were analysed using Cox proportional hazards models with AVR as a time-dependent covariate.
Late survival was lower in patients with untreated moderate AS (12 years 23 ± 5.1%) versus mild (42 ± 3.8%) or no AS (38 ± 3.3%) (P = 0.01). Adjusting for age, ejection fraction, heart failure, creatinine, diabetes, peripheral vascular disease (PVD) and interval AVR, moderate AS independently predicted higher mortality [hazard rate (HR) 2.01, 95% confidence interval (CI) 1.49-2.73; P < 0.001]; whereas incremental risk was insignificant for patients with mild AS (HR 1.09, 95% CI 0.85-1.66; P = 0.33). Further stratification showed that highest late postoperative mortality occurred with an AVA of 1-1.25 cm(2) (adjusted HR 2.45, 95% CI 1.57-3.82; P < 0.001), while risk was intermediate with an AVA of 1.25-1.5 cm(2) (HR 1.83, 95% CI 1.28-2.61; P = 0.001).
Untreated moderate AS is an independent determinant of excess late mortality following isolated CABG, and mortality risk increases with decreasing AVA. Those with moderate-to-severe AS (AVA 1-1.25 cm(2)) have more than 2-fold greater long-term mortality compared with those without AS. These data define AS severity thresholds for clinical trials aimed at defining whether valve intervention might mitigate this risk.
对于严重主动脉瓣狭窄(AS)患者,在冠状动脉旁路移植术(CABG)时进行主动脉瓣置换(AVR)属于I类适应证。然而,CABG患者中轻度以下AS的管理尚不确定,因为未经治疗的AS影响长期预后的阈值尚不清楚。
我们纳入了1993年至2006年间接受单纯CABG且患有轻度或中度AS[主动脉瓣面积(AVA)1-2 cm²]的312例患者,并将他们与同期接受单纯CABG且具有相似特征但无AS(AVA>2 cm²)的患者进行匹配。使用Cox比例风险模型分析CABG后的长期生存率及其决定因素,并将AVR作为时间依赖性协变量。
未经治疗的中度AS患者的晚期生存率低于轻度(42±3.8%)或无AS(38±3.3%)的患者(12年时为23±5.1%)(P=0.01)。校正年龄、射血分数、心力衰竭、肌酐、糖尿病、外周血管疾病(PVD)和间隔期AVR后,中度AS独立预测更高的死亡率[风险比(HR)2.01,95%置信区间(CI)1.49-2.73;P<0.001];而轻度AS患者的额外风险不显著(HR 1.09,95%CI 0.85-1.66;P=0.33)。进一步分层显示,术后晚期死亡率最高的是AVA为1-1.25 cm²的患者(校正HR 2.45,95%CI 1.57-3.82;P<0.001),而AVA为1.25-1.5 cm²的患者风险处于中等水平(HR 1.83,95%CI 1.28-2.61;P=0.001)。
未经治疗的中度AS是单纯CABG术后晚期额外死亡的独立决定因素,且死亡风险随AVA降低而增加。与无AS的患者相比,中度至重度AS(AVA 1-1.25 cm²)患者的长期死亡率高出2倍多。这些数据为旨在确定瓣膜干预是否可降低该风险的临床试验定义了AS严重程度阈值。